secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2023-06-29T23:59:59+00:00
Accession:  0001104659-23-075997
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar stockholders approve 1.1M share increase to stock plan, re-elect directors
--------------------------------------------------------------------------------

- Stockholders approved 1,100,000-share increase to 2021 Stock Incentive Plan (3,025,557 for, 389,584 against).
- Class III directors Stefan D. Loren, Ph.D. and Douglas J. Swirsky re-elected to three-year terms.
- Ratification of Baker Tilly US, LLP as independent auditor for FY2023 approved (5,283,070 for, 54,947 against).
- Non-binding advisory vote on executive compensation approved (3,100,012 for, 311,122 against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/0001104659-23-075997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465923075997/tm2319838d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-075997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer